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Abstract This study aims to review clinical features, treat-
ments, and prognostic factors of thrombotic thrombocytopenic
purpura (TTP) associated with systemic lupus erythematosus
patients (sTTP). The case reports of sTTP published in world
literature from 1999 to 2011were collected, and 105 cases were
divided into death group and survival group. The epidemiolog-
ic characteristics, clinical manifestations, laboratory examina-
tions, treatments, and prognostic factors were analyzed. We
found that coexistence of renal and neurological impairments
were significantly frequent in the death group (100 %) than in
the survival group (56.5 %) (P=0.002). Type IV was predom-
inant in 57.7 % of renal pathological damage, followed by type
V (11.5 %), type II (5.8 %), and thrombotic microangiopathy
(TMA) (5.8 %). TMA appeared more frequently (50 %) in the
death group than in the survival group (6.25 %) (P=0.042).
End-stage renal disease occurred in nine cases with type IV in
five (55.6 %), type TMA in one (11.1 %), and unspecified in
three cases (33.3 %). Of 32 cases, 40.6 % showed severe
ADAMTS13 deficiency and returned to normal or mildly
deficient after remission. The total mortality rate of sTTP was
12.4% and themortality rate of patients with infection (27.3%)
was significantly higher than those without infection (8.4 %)
(P=0.028). Plasma exchange and glucocorticoids were admin-
istrated in over 80% of cases with 65.7 % remission rate, while
additional cytotoxics or rituximab was mostly used in refracto-
ry sTTP and achieved over 90 % of remission rate. Above all,
coexistence of renal and neurological impairments, infection,
and renal damage with type IV or TMA might denote a poor
prognosis of sTTP.
Keywords ADAMTS13 . Infection . Prognostic factors .
Systemic lupus erythematosus . Thrombotic
thrombocytopenic purpura
Introduction
Thrombotic thrombocytopenic purpura (TTP) is an uncom-
mon thrombotic microangiopathy (TMA) characterized with a
clinical pentad: thrombocytopenia, microangiopathic hemo-
lytic anemia (MAHA), fever, neurological deficits, and renal
dysfunction. Apart from some idiopathic cases, TTP may
occur secondary to infections, malignancy, drugs, pregnancy,
and autoimmune diseases such as systemic lupus
erythematosus (SLE) [1]. Although plasma exchange dramat-
ically improved the prognosis of TTP with over 80 % of
survival rate [2], the episode will be severe and lethal (from
34.1 to 62.5 % morality rate) when TTP occurs in patients
with SLE (referred as sTTP) [3, 4]. In addition, the diagno-
sis of TTP in the setting of SLE may be challenging
because both of them share some or all elements of the
classic pentad mentioned above [5], which in turn will
delay the initialization of effective treatment. Moreover,
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the response to therapy appeared to be poorer in sTTP
than idiopathic TTP (iTTP) patients [3]. Furthermore,
how sTTP occurs and how to improve its prognosis
remain unclear until now.
In the last two decades, autoimmunity or vasculopathy with
endothelial damage and platelet aggregation was considered as
the pathogenesis of TTP in the setting of SLE [4, 6]. In 1998,
Musio et al. [4] demonstrated that endothelial damage related to
autoantibodies, platelet abnormalities, and disorders of fibrino-
lysis shared by both SLE and TTP might partially explain the
generation and development of TMA according to 40 reports of
sTTP from world literatures. In addition, excess of hemoglobin
and increase of thrombin and D-dimer may also offer insights
into the microangiopathic process of TTP [6, 7]. In recent years,
an autoimmunity mechanism was proposed to be more impor-
tant to the onset of TTP in the context of SLE, which was
supported by the presence of various antibodies such as anti-
endothelial cell antibody, antiplatelets antibody [3, 8], and anti-
ADAMTS13 (von Willebrand factor cleaving metalloprotease)
antibody [6]; this was further supported by the successful
treatment of sTTP with cytotoxics and rituximab [9, 10]. Al-
though the deficiency of ADAMTS13 activity related to its
inhibitory IgG antibodies plays an important role in idiopathic
TTP patients [1], it is still unclear whether both of them take
part in the pathogenesis of sTTP and affects the treatment and
prognosis of sTTP due to its rare incidence and limited reports.
In this study, we reviewed the worldwide literatures over
more than 10 years (from January 1999 to December 2011),
systematically analyzed epidemiologic characteristics, clinical
manifestations, laboratory examinations, and treatments of 105
sTTP cases. Moreover, we divided the total cases into two
groups (death group and survival group) and tried to find some
factors characteristically involved in the prognosis of sTTP.
Patients and methods
Data collection
We searched Medline, Embase, Elsevier, and China National
Knowledge Infrastructure Database for articles to identify all
reported cases of sTTP published from January 1999 to Decem-
ber 2011 with the following terms: “systemic lupus
erythematosus” or “SLE” and “thrombotic thrombocytopenic
purpura” or “TTP.” Articles published in English and other
languages were all included. Our initial search revealed 81
references. We excluded 16 studies in which TTP cases were
not associated with SLE. Because Musio et al. [4] systemically
reviewed 40 cases of sTTP reported in world literatures before
1998, the cases documented before 1998 or studies without
detailed records in five references were also excluded. Finally,
we collected 105 cases in 60 references from January 1999 to
December 2011 (the 60 references were not presented for request
of reference numbers in instructions for authors).
Definition
Diagnosis definition Selected cases were identified with sTTP
according to both SLE and TTP diagnosis criteria. All selected
cases met the 1982 revised criteria for the classification of SLE
[11]. Because no clinical symptom or biological criterion avail-
able is specific for TTP until now, the diagnosis of TTP in the
selected cases was determined by the association of MAHA and
unexplained thrombocytopenia as two major criteria, along with
at least one of three minor criteria including fever, neurological
deficits, and renal impairment, followed by exclusion of other
causes for thrombocytopenia such as autoimmune hemolytic
anemia, disseminated intravascular coagulation, cancer, eclamp-
sia, drug toxicity, stem cell transplantation, or malignant hyper-
tension [1, 2, 6]. SLE may occur before, simultaneously, or after
the diagnosis of TTP. The simultaneous diagnosis of TTP and
SLEwas considered if both disorders were diagnosed during the
same admission within a 14-day period [12].
Outcome definition sTTP remission is defined as laboratory
and clinical abnormalities typically resolved with normal
neurological status and platelet count [3, 13]. Refractory
disease or resistance is defined as persistent thrombocytope-
nia (platelet <150,000 μL) or LDH elevation or organ in-
volvement after a total of seven daily plasma exchanges and
(or) intensive immunosuppressive therapy [3, 14]. Survival
is defined as achievement of remission [13]. Death from TTP
is defined as occurring within 30 days of stopping plasma
exchange in two studies [13, 15]. After reviewing the liter-
ature concerning the 105 cases, we found that the follow-up
data in most reports were not presented in detail. Therefore,
we define death from sTTP as occurring within the hospital-
ization period with a clearly diagnosis of sTTP, and deaths
beyond the hospitalization period was not taken into account.
Relapse is defined as the recurrence of thrombocytopenia
and MAHA after remission is achieved [13, 15].
Data synthesis and analysis
All data including gender, age, sequence of disease onset (SLE
preceding TTP or SLE following TTP or SLE concomitant with
TTP), major clinical features, laboratory examination, treatment,
and prognosis in each case were entered and analyzedwith SPSS
version 19.0. Laboratory data recorded gave the most abnormal
values when sTTP was diagnosed. According to the outcome
during hospitalization period, all 105 cases were divided into the
death group (13 cases) and the survival group (92 cases). Nu-
merical data were compared by the independent-samples t test or
Welch’s t test. The qualitative differences were performed using
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chi-square test or Fisher’s exact test. P<0.05 was considered to
be a significant difference between the groups.
Results
Epidemiologic characteristics
There were 18 males (17.1 %) and 87 females (82.9 %) in
105 cases. The mean age was 32.3±13.4 years ranging from
8 to 74 years (median age, 30 years). The onset of SLE
preceded, coincided, or followed the onset of TTP in 53
cases (50.5 %), 48 cases (45.7 %), and 4 cases (3.8 %),




In our study, 17 initial clinical manifestations involving over
seven systems and organs were described in detail in 68 patients
(Table 1). The most common complaints were recurrent fever
(19.1 %), followed by fatigue (16.2 %) and headache (14.7 %).
Neurological deficits
Neurological symptoms occurred in 80 (76.2 %) of 105
sTTP cases. Among the 80 cases, neurological symptoms
were described clearly in 69, with single neurological symp-
tom in 31 (44.9 %) and more than one symptom in 38
(55.1 %). Eight types of neurological symptoms were
presented, including disturbance of consciousness (41 cases,
59.4 %), seizures (33 cases, 47.8 %), headache (19 cases,
27.5 %), mental confusion (13 cases, 18.8 %), optic nerve
damage (7 cases, 10.1 %), hemiparesis (6 cases, 8.7 %),
peripheral nerve palsy (4 cases, 5.8 %), and language disor-
der (4 cases, 5.8 %). In the death group, all 13 patients
(100 %) had neurological symptoms, which were significant-
ly frequent than in the survival group (67 of 92 cases,
72.8 %) (χ2=4.637, P=0.035). Among the 80 cases with
neurological symptoms, 44 underwent head imaging tests
(CT or MRI) and 22 cases (50 %) presented positive results
including cerebral infarction and (or) ischemic lesions in 17
Table 1 Initial clinical manifes-
tations in 105 sTTP patients Initial clinical manifestations Total cases Death group Survival group
(n=68) (n=11) (n=57)
General manifestation
Recurrent fever 13 3 10
Fatigue 11 1 10
Rash
Ecchymosis 4 0 4
Gastrointestinal system
Abdominal pain 6 2 4
Jaundice 2 0 2
Vomit 1 1 0
Respiratory system
Dyspnea 5 1 4
Chest pain 2 0 2
Urinary system
Edema 3 0 3
Dark urine 3 2 1
Neurologic system
Headache 10 1 9
Conscious disturbance 2 0 2
Seizures 2 0 2
Language disorder 1 0 1
Paresthesia 1 0 1
Motor system
Arthralgia 1 0 1
Gynecologic system
Hypermenorrhea 1 0 1
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cases (77.3 %), leukodystrophy in 3 (13.6 %), and cerebral
hemorrhage in 4 (18.1 %).
Renal impairment
Among 105 patients, 88 (83.8 %) cases showed renal impair-
ment such as proteinuria, hematuria, increase of plasma urea
nitrogen and creatinine, and renal failure, including all 13
cases (100 %) in the death group and 75 of 92 cases
(81.5 %) in the survival group. Fifty-two of 88 cases
(59.1 %) took a kidney biopsy and revealed 11 types of renal
pathological damage. Type IV was predominant in 57.7 % of
renal pathological damage, followed by type V (11.5 %), type
II (5.8 %), and TMA (5.8 %) (Table 2). TMA appeared more
frequently (2 of 4 cases, 50 %) in the death group than in the
survival group (3 of 48 cases, 6.25 %) (χ2=8.132, P=0.042).
The end-stage renal disease occurred in 9 of 88 (10.2 %) cases
with type IV kidney damage in five (55.6 %), type TMA in
one (11.1 %), and unspecified in three cases (33.3 %).
Neurological deficits together with renal impairment
Among 105 cases, both neurological deficits and renal im-
pairment were seen in 65 (61.9 %) cases including all 13
cases (100 %) in the death group and 52 cases (56.5 %) in the
survival group. Coexistence of renal and neurological im-
pairments were significantly frequent in the death group than
in the survival group (χ2=9.130, P=0.002).
Laboratory examinations
Thrombocytopenia, anemia, and elevated LDH were shown
in 105 (100 %), 97 (92.4 %), and 86 (81.9 %) cases, and the
levels of PLT, Hb, and LDH were 39.3±31.1×109/L,
71.1±22.1 g/L, and 1,304±1,575 IU/L, respectively. A pe-
ripheral blood smear test was elaborately described in 99
cases, and all showed schistocytes (usually >1 % of total
erythrocytes).
Coombs’ tests were detailed in 80 of 105 patients with a
negative rate of 77.5 % (62 cases). ADAMTS13 activities
were tested before treatment in 32 patients, with severe defi-
ciency (<5 % of normal) in 13 cases (40.6 %), moderate
deficiency (10–25 %) in 2 cases (6.3 %), mild deficiency
(26–50 %) in 12 cases (37.5 %), and normal (>50 %) in 5
cases (15.6 %) [10]. ADAMTS13 activities were re-examined
in 14 cases after remission. The levels of ADAMTS13 activ-
ities were elevated in all 14 cases, with normal levels in 10
cases, and mild deficiency in 4 cases. Anti-ADAMTS13
antibody was tested in 24 patients with positive rates of
91.7 % in 22 cases. Positive rates of main immunological
parameters were summarized in detail in Table 3. All abnor-
mal values mentioned above were not significantly different
between the death group and the survival group (P>0.05).
Treatment and prognosis
Combination therapies were widely used in sTTP patients,
and the most common therapeutic modalities were plasma
exchange combined with glucocorticoids pulse therapy and
cytotoxic agents (in 52 cases, 49.5 %), followed by plasma
exchange combined with glucocorticoids pulse therapy (in 35
cases, 33.3 %) (Table 4). Among the combination therapies,
glucocorticoids were administrated in 99 cases (94.3 %). Plas-
ma exchange and (or) hematodialysis and (or) plasma infusion
were used in 95 cases (90.5 %). When plasma exchange was
absent in 10 cases, the refractory and mortality rates were as
high as 60 and 30 %, respectively (Table 4). Several cases
were refractory to one therapy (e.g., plasma exchange with
glucocorticoids pulse therapy) but responded to additional
cytotoxics or rituximab. Combination therapies with cyto-
toxics could significantly improve the remission rate when
comparedwith therapieswithout cytotoxics (P<0.05, Table 4).
Table 2 Renal pathological
damages in 105 sTTP patients
TMA thrombotic
microangiopathy
a TMA appeared more frequently
(50 %) in the death group than in
the survival group (3 of 48 cases,
6.25 %) (χ2 =8.132, P=0.042)
by using Fisher’s exact test
Renal pathological damages Total cases Death group Survival group
(n=52) (n=4) (n=48)
IV 30 1 29
V 6 0 6
TMAa 3 2 1
II 3 1 2
III 2 0 2
VI 2 0 2
III and V 1 0 1
IV and V 1 0 1
V and TMAa 1 0 1
VI and TMAa 1 0 1
II and III 1 0 1
Normal 1 0 1
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The most common cytotoxic agents for treatment was cyclo-
phosphamide (52 cases, 49.5 %), mycophenolate mofetil (16
cases, 15.2 %), and vincristine (8 cases, 7.6 %). Furthermore,
plasma exchange combined with glucocorticoids pulse therapy
were seemed to be widely used in cases with normal or slightly
deficiency of ADAMTS13 activity, while combination with
additional cytotoxics or rituximab were frequently used to treat
cases with severely or moderately deficient ADAMTS13 activity
(Table 5). Besides therapies mentioned above, intravenous
immunoglobin, anticoagulant drugs, erythropoietin, and erythro-
cyte or platelet transfusion were also chosen in several cases.
The total mortality rate was 12.4 % and the main causes of
death included sTTP itself (single or multiple organ failure) and
(or) in combination with overwhelming infection (Table 4).
Twenty-two (21 %) patients suffered from an infection in which
pneumonia was predominant in 17 cases (77.3 %). The
pathogenic microorganisms included Staphylococcus aureus,
Staphylococcus epidermidis, Pseudomonas, Pneumocystis
carinii, Aspergillus, and Cytomegalovirus. The mortality of pa-
tients with an infection (6 of 22 cases, 27.3 %) was significantly
higher than patients without an infection (7 of 83 cases, 8.4 %)
(χ2=5.690, P=0.028). Forty-six patients were followed up for a
mean time of 25.3±26.5 months (ranging from 2 to 96 months).
Seven patients (15.2 %) had relapse records of TTP (mean 2.43
times, ranging from one to nine times) during follow-up.
Comparison with cases before 1998 [4]
The incidence of patients with SLE concomitant with TTP (48
cases, 45.7 %) in our study was significantly more than before
1998 (5 cases, 12.2 %), while the cases with SLE preceding (53
cases, 50.5 %) or following (4 cases, 3.8 %) TTPwere both less
Table 3 Positive rates of main
immunological parameters in
105 sTTP patients
Antibodies Total Death group Survival group
n (%) n (%) n (%)
Anti-ANA 94/97 (96.9) 12/12 (100) 82/85 (96.5)
Anti-dsDNA 56/97 (57.7) 5/12 (41.7) 51/85 (60)
Anti-Sm 20/97 (20.6) 2/12 (16.7) 18/85 (21.2)
Anti-phospholipid antibody 19/64 (29.7) 2/6 (33.3) 17/58 (29.3)
ADAMTS13 activities (<5 %) 13/32 (40.6) 2/3 (66.7) 11/29 (37.9)
anti-ADAMTS13 antibody 22/24 (91.7) 2/2 (100) 20/22 (90.9)
Table 4 Various therapies and their recorded outcome in 105 sTTP cases











n (%) n (%) n (%) n (%) n (%)
PE aloneb 6 (6.7) 3/6 (50) 3/6 (50) 2/6 (33.3) 1/6 (16.7) sTTP
ST and (or) cytotoxics
without PEc
10 (9.5) 4/10 (40) 6/10 (60) 3/10 (30) 3/10 (30) sTTP (single organ failure)
PE + STd 35(33.3) 23/35 (65.7) 12/35 (34.3) 8/35 (22.9) 4/35 (11.4) Overwhelming
infection/sTTP
(multiple organ failure)
PE + cytotoxics 3 (2.9) 3/3 (100) 0 0 0 No
PE + ST + cytotoxicse 52 (49.5) 47/52 (90.4) 5/52 (9.6) 0 5/52 (9.6) Refractory sTTP/
overwhelming infection
Rituximab + PE with or
without ST (or cytotoxics)
11 (10.5) 10/11 (90.9) 1/11 (9.1) 1/11 (9.1) 0 No
Others 2 (2.9) 2/2 (100) 0 0 0 No
PE plasma exchange and(or) hematodialysis and(or) plasma infusion, ST steroids (glucocorticoids), mostly pulse methylprednisolone therapy,
cytotoxics including cyclophosphamide, mycophenolate mofetil, vincristine, cyclosporine A, and methotrexate, others including rTM (recombinant
human soluble thrombomodulin) in one and bilateral nephrectomy in the other




e The remission rate by using the therapy (PE + ST + cytotoxics) was significantly higher than the other three therapies (PE alone, ST and (or)
cytotoxics without PE, and PE + ST)
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than before 1998 (30 cases/73.2 % and 6 cases/14.6 %, respec-
tively) (P<0.05, Table 6). The mortality rate (12.4 %) in our
review from 1999 to 2011 was significantly lower than before
1998 (34.1 %) [4] (χ2=9.267, P=0.004).
Discussion
The initial clinical manifestations are easily ignored in sTTP
patients due to non-specification, in which the most com-
plaints are commonly related to the early TTP, such as
neurological deficits (e.g., headache, conscious disturbance,
ischemia associated), fatigue, and abdominal pain (bleeding
associated) [1, 5]. Meanwhile, we found that neurological
deficits and renal impairment occurred frequently in 76.2 and
83.8 % of cases, respectively. The occurrence of neurological
deficits alone or accompanied by renal impairment was
significantly higher in the death group than in the survival
group, which suggested that neurological deficits especially
together with renal impairments might be a possible prog-
nostic factor for sTTP patients although the accuracy of
using this tenuous relation is debatable. The poor eventual
treatment outcome might be related to two factors. In the first
place, acute ischemia related to thrombotic microangiopathy
is common in TTP [1, 3, 16], which is also supported by the
head imaging tests in this review with ischemic lesions
occurring in 77.3 % of the cases. In the second place, the
brain will be the most common target for ischemia [1]. In
addition, Kwok et al. [17] also found that SLE patients with
neurologic manifestations had a higher mortality rate.
Table 5 Various therapies and recorded outcome in 32 cases with different ADAMTS 13 activity
Various therapies ADAMTS 13 activity ADAMTS 13 activity ADAMTS 13 activity ADAMTS 13 activity
(<5 % of normal) (10–25 %) (25–50 %) (>50 %)
(N=13) (N=2) (N=12) (N=5)
PE alone NR NR 1 died 1 Rfa
ST and (or) cytotoxics NR 1 Rm 1 Rm 1 Rfa
PE + ST pulse therapy 7 Rm, 2 Rfa 1 Rm 1 Rm NR
2 died
PE + cytotoxics 1 Rm NR 1 Rm NR
PE + ST pulse therapy + cytotoxics 2 Rm NR 6 Rm 1 Rm
Rituximab + PE with or without
ST (or cytotoxics)
1 Rm NR 2 Rm 3 Rm
rTM NR NR NR 1 Rm
PE plasma exchange and (or) hematodialysis and (or) plasma infusion, ST steroids (glucocorticoids), mostly with pulse methylprednisolone therapy,
cytotoxics including cyclophosphamide, mycophenolate mofetil, vincristine, cyclosporine A, and methotrexate, rTM recombinant human soluble
thrombomodulin, Rf refractory, Rm remission, NR not reported
a The patient was refractory to one therapy but achieved remission by additional therapy such as cytotoxics or rituximab
Table 6 Epidemiologic characteristics and mortality rate of sTTP at different times

















41 5 (12.2) 36 (87.8) 30 (73.2) 6 (14.6) 5 (12.2) 6 (14.6) 29 (70.7) 6 (14.6)
1999–2011,
n (%)
105 18 (17.1) 87 (82.9) 53 (50.5) 4 (3.8) 48 (45.7) 21 (20) 70 (66.7) 14 (13.3)
Mortalitya Before 1998,
n (%)
14/41 (34.1) 2/5 (40.0) 12/36 (33.3) 13/30 (43.3) 0 1/5 (20) 1/6 (16.7) 12/29 (41.4) 1/6 (16.7)
1999–2011,
n (%)
13/105 (12.4) 2/18 (11.1) 11/87 (12.6) 7/53 (13.2) 1/4 (25) 5/48 (10.4) 1/21 (4.8) 8/70 (11.4) 4/14 (28.6)
The cases before 1998 were presented in Musio’s review[4], and the data from 1999 to 2011 was reviewed in this study
a They were significantly different between Musio’s review and our study, including the total mortality (χ2 =9.267, P=0.004), cases with SLE
preceding TTP (χ2 =6.191, P=0.013), SLE following TTP (χ2 =5.415, P=0.03), and SLE concomitant with TTP (χ2 =14.327, P=0.00)
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Among the 105 sTTP cases, the most common renal path-
ological damage was type IV (57.7 %), followed by type V
(11.5 %), type II (5.8 %), and TMA (5.8 %). The findings
were supported by Mustafa et al. [18] who presented that type
IV was predominant in 60 % SLE cases. In addition, renal
TMA usually occurs in patients with severe lupus nephritis
[8], and TMA also adversely affect the prognosis of the renal
disease [19]. We found that type IV was not only the most
common type in sTTP patients but also capable of evolving
end-stage renal disease than other types, and TMA appeared
more frequently in the death group. Thus, renal damage of
type IV or TMA may be another risk factor related to poor
prognosis of sTTP. Conducting a renal pathological biopsy at
an early stage could be helpful for evaluating disease condi-
tion and prognosis.
Apart from thrombocytopenia, MAHA, and elevated LDH,
negative Coombs test, dysfunction of ADAMTS13, and anti-
ADAMTS13 antibody are also reported to be crucial for mak-
ing an early diagnosis of TTP [2]. However, we found that
22.5 % of cases had a positive direct Coombs test along with
clear features of TTP. Therefore, a Coombs test may be positive
in sTTP as part of immune phenomena of SLE and is not
necessarily against the diagnosis sTTP. ADAMTS 13, a vWF
(Von Willebrand Factor) cleaving metalloprotease, which is
caused by either an autoimmune inhibitor or genetic mutation,
is referred as one of the causative factors of TTP [6]. ADAMTS
13 deficiency will result in formation of ultra-large vWF
multimers and thrombosis in TTP. Although about two thirds
to three quarters of patients with iTTP have been found to be
severely deficient in ADAMTS13 activity [2, 20], only 40.6 %
of sTTP cases were presented with severe deficiency in our
study. Inconsistent with less than half of patients with severe
ADAMTS13 deficiency, anti-ADAMTS13 antibodywas found
in 91.7 % of cases. These results might be associated with
following factors. Firstly, severe deficiency of ADAMTS13
might be alleviated by immunosuppressive drugs by suppress-
ing the formation or function of anti-ADAMTS13 antibody.
Secondly, although most patients had anti-ADAMTS13 anti-
body, a few of them may have anti-ADAMTS13 antibody
without neutralizing activity [6]. Thirdly, detection time also
needs to be considered because the level of ADAMTS13
activity fluctuates during the process of disease. It has been
reported that many iTTP patients usually have severe
ADAMTS13 dysfunction or even lack ADAMTS13 activity
only during an initial episode or later recurrence [2].
Meanwhile, we also found that severe or moderate defi-
ciency of ADAMTS13 mostly (75 %) became normal after
remission. More interestingly, sTTP with severe or moderate
deficiency of ADAMTS13 were mostly treated with simple
therapies (e.g., plasma exchange combined with glucocorti-
coids pulse therapy) [21–24], while cases with normal or
slightly ADAMTS13 deficiency responded well to additional
cytotoxics or rituximab [19, 25, 26]. From the above findings,
monitoring the level of ADAMTS13 activity might be advan-
tageous to determining the approach for treating sTTP patients
and assessing the approach’s efficacy, but more cases are
needed to further evaluate its value for the diagnosis and
treatment of sTTP. TTP with severe ADAMTS13 deficiency
was also reported to have a higher likelihood of relapse [2,
27], but it was not shown in this review due to the lack of
follow-up data.
Early use of plasma exchange shows good efficacy for iTTP
with over 80% of survival rate [3, 13, 17]. This approach is also
useful in treating sTTP. In 10 cases without receiving plasma
exchange, the refractory and mortality rates of sTTP were as
high as 60 and 30 %, respectively, in this review. However,
plasma exchange alone is not enough to control TTP in the
setting of SLE. Combined therapies with plasma exchange and
immunosuppressor (including steroids and cytotoxic agents)
were presented to be more appropriate than plasma exchange
or immunosuppressor alone in treating sTTP patients and
achieved a higher remission rate (65.7–90.4 % vs 40–50 %)
in this review. This result was also supported by Letchumanan
et al. who reported that TTP patients in the setting of SLE were
more refractory to plasma exchange and had a poorer prognosis
than iTTP [3]. In this review, plasma exchange combined with
glucocorticoids remained the first-line treatment due to over
80 % utilization rate and 65.7 % remission rate. However,
several cases were refractory to plasma exchange combined
with glucocorticoids (34.3 % refractory rate). On this occasion,
cytotoxics should be considered in several reports [10, 28]. Our
review further confirmed this point, in which plasma exchange
combined with glucocorticoids pulse therapy and cytotoxic
drugs could significantly improve the remission rate (90.4 %,
P<0.05) when compared with therapies without cytotoxics.
In addition, except cytotoxics, biological therapy such as
rituximab (a chimeric monoclonal antibody against the pro-
tein CD20, which depletes B lymphocytes) was also recom-
mended by successfully treating refractory sTTP patients
(90.9 % remission rate) in several cases [9, 25, 26, 29] in
this review. It has been shown that rituximab could remove
ADAMTS13 inhibitor and improve clinical outcomes in
TTP [9, 25]. In this review, rituximab was not only effective
for sTTP cases with impaired ADAMTS13 activity [29] but
also useful for cases with normal ADAMTS13 activity [25,
26]. However, owing to the small number of cases treated
with rituximab in this review, the value of rituximab in
treating refractory sTTP requires to be further evaluated.
The total mortality of 105 sTTP cases in this review was
12.4 %, which was significantly lower than 34.1 and 62.5 % in
reported in two reviews [3, 4]. This may be attributed to
following factors. Firstly, earlier diagnosis and more effective
treatment (mentioned above) were realized compared with
before. Secondly, deaths beyond the hospitalization period
were not taken into account in this review due to lack of
follow-up data. In addition, we also found that the mortality
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rate in patients with infection (27.3 %) was significantly higher
than those without infection (8.4 %), and overwhelming infec-
tion was also one of the main causes of death. Besides renal
damage type (IVor TMA), and concomitant occurrence of renal
and neurological impairments, infectionmight be considered as
the third poor prognosis factor for sTTP. This result was con-
sistent with Kwok’ study [17] which showed that sTTP can be
fatal especially in the presence of infection. Infection is obvi-
ously related to the use of immunosuppressant and biological
therapy, so aseptic conditions for treatment and infection pre-
vention would be helpful for a more favorable prognosis.
Although some findings mentioned above are both interest-
ing and useful for a physician to engage a patient with sTTP,
several limitations are obvious. Firstly, retrospective data col-
lection from case reports will not be as rigorous as a prospective
study. In addition, some laboratory evaluations were not
completely consistent due to cases from different countries,
which could influence the analysis of laboratory data. Finally,
the data among three groups (SLE preceding TTP, SLE follow-
ing TTP, and SLE concomitant with TTP) were not able to be
presented and analyzedmeaningfully due to the relatively fewer
cases in SLE following TTP group (only four cases), which
limited the statistical power for comparisons.
Conclusion
In conclusion, plasma exchange combined with glucocorti-
coids remains the first-line treatment for sTTP, while cyto-
toxic agents and biological therapy are recommended for
refractory sTTP. Coexistence of neurologic and renal impair-
ments, renal damage with type IV or TMA, and infection
might be three risk factors for poor prognosis of sTTP.
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